| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 17th July 2020 | Robert Janssen | 50,000 | Open or private sale | $11.09 | $554,500.00 |
| 27th May 2020 | Andrew A. F. Hack | 1,000,000 | Open or private purchase | $5.00 | $5,000,000.00 |
| 19th May 2020 | Robert Janssen | 15,000 | Open or private sale | $6.33 | $94,950.00 |
| 6th May 2020 | Robert Janssen | 28,000 | Open or private sale | $4.52 | $126,560.00 |
| 5th May 2020 | Robert Janssen | 9,000 | Open or private sale | $4.43 | $39,870.00 |
| 7th April 2020 | Andrew A. F. Hack | 2,800,000 | Open or private purchase | $5.59 | $15,652,000.00 |
| 7th April 2020 | Andrew A. F. Hack | 645,667 | Open or private purchase | $7.74 | $4,997,462.58 |
| 16th March 2020 | Michael S Ostrach | 12,684 | Payment by withholding | $2.32 | $29,426.88 |
| 16th March 2020 | Michael S Ostrach | 4,901 | Payment by withholding | $2.32 | $11,370.32 |
| 16th March 2020 | Michael S Ostrach | 27,352 | Payment by withholding | $2.32 | $63,456.64 |
Dynavax Technologies
Dynavax Technologies Corp. is a biopharmaceutical company. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996.
Ticker: DVAX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1029142
Employees: 231
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $38 M (0%)
Inventory, Net: $48 M (0%)
Assets, Current: $194 M (-6%)
Property, Plant and Equipment, Net: $31 M (-3%)
Other Assets, Noncurrent: $3 M (-1%)
Assets: $259 M (-7%)
Accounts Payable, Current: $5 M (-50%)
Accrued Liabilities, Current: $12 M (-17%)
Liabilities, Current: $29 M (-44%)
Long-term Debt, Excluding Current Maturities: $180 M (0%)
Other Liabilities, Noncurrent: $2 M (24%)
Liabilities: $247 M (-8%)
Common Stock, Value, Issued: $88 Th (4%)
Common Stock, Shares, Issued: $88 Th (4%)
Additional Paid in Capital, Common Stock: $1 B (1%)
Retained Earnings (Accumulated Deficit): $1 B (1%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $3 M (7%)
Stockholders' Equity (Parent): $12 M (0%)
Liabilities and Equity: $259 M (-7%)
Revenue: $11 M (89%)
Research and Development: $5 M (-78%)
Operating Income/Loss: $19 M (-48%)
EPS (basic): $0.15 (-75%)
EPS (diluted): $0.25 (-59%)
News
US shale producers Devon, WPX Energy in merger talks
26th September 2020
Mitsubishi Motors to cut 500-600 jobs to reduce costs-sources
26th September 2020
Apple Fitness Plus’ biggest competitor isn’t Peloton — it’s your gym
26th September 2020